George Massaro Sells 3,140 Shares of Charles River Laboratories Intl. Inc (CRL) Stock

Charles River Laboratories Intl. Inc (NYSE:CRL) Director George Massaro sold 3,140 shares of the company’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $134.64, for a total transaction of $422,769.60. Following the sale, the director now directly owns 15,344 shares of the company’s stock, valued at approximately $2,065,916.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NYSE:CRL opened at $131.63 on Thursday. The company has a market cap of $6.39 billion, a price-to-earnings ratio of 21.83, a PEG ratio of 1.69 and a beta of 0.99. Charles River Laboratories Intl. Inc has a fifty-two week low of $102.96 and a fifty-two week high of $149.07. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.63 and a quick ratio of 1.39.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.38 by $0.02. Charles River Laboratories Intl. had a return on equity of 23.03% and a net margin of 9.63%. The business had revenue of $604.57 million for the quarter, compared to analysts’ expectations of $587.65 million. During the same period last year, the business earned $1.29 EPS. The business’s revenue was up 22.4% on a year-over-year basis. On average, sell-side analysts expect that Charles River Laboratories Intl. Inc will post 6.47 EPS for the current year.

Large investors have recently modified their holdings of the business. Norges Bank bought a new stake in shares of Charles River Laboratories Intl. during the 4th quarter worth $61,460,000. Epoch Investment Partners Inc. purchased a new stake in Charles River Laboratories Intl. in the 4th quarter worth about $39,002,000. AQR Capital Management LLC increased its holdings in Charles River Laboratories Intl. by 18.0% in the 1st quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock worth $301,042,000 after acquiring an additional 317,001 shares during the last quarter. OZ Management LP purchased a new stake in Charles River Laboratories Intl. in the 1st quarter worth about $44,308,000. Finally, Assenagon Asset Management S.A. increased its holdings in Charles River Laboratories Intl. by 361.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 335,619 shares of the medical research company’s stock worth $48,749,000 after acquiring an additional 262,907 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

CRL has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a $162.00 price objective on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. SunTrust Banks upped their price objective on shares of Charles River Laboratories Intl. to $151.00 and gave the stock a “buy” rating in a research report on Thursday, February 14th. Barclays reaffirmed a “hold” rating and set a $135.00 price objective on shares of Charles River Laboratories Intl. in a research report on Thursday, February 14th. Finally, KeyCorp upped their price objective on shares of Charles River Laboratories Intl. from $140.00 to $151.00 and gave the stock an “overweight” rating in a research report on Monday, March 11th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Charles River Laboratories Intl. currently has a consensus rating of “Buy” and an average target price of $145.64.

TRADEMARK VIOLATION NOTICE: “George Massaro Sells 3,140 Shares of Charles River Laboratories Intl. Inc (CRL) Stock” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2019/05/16/george-massaro-sells-3140-shares-of-charles-river-laboratories-intl-inc-crl-stock.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: Why is a lock-up period needed for an IPO?

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.